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Abstract. While the etiology of Alzheimer’s disease (AD) is still unknown, an increased formation of amyloid- (A)
peptide and oxidative processes are major pathological mechanism of the disease. The interaction of A with free heme
leads to the formation of peroxidase-active A-heme complexes. However, enzyme-kinetic data and systematic mutational
studies are still missing. These aspects were addressed in this study to evaluate the role of A-heme complexes in AD.
The enzyme-kinetic measurements showed peroxidase-specific pH- and H2O2-dependencies. In addition, the enzymatic
activity of A-heme complexes constantly increased at higher peptide excess. Moreover, the role of the A sequence for
the named enzymatic activity was tested, depicting human-specific R5, Y10, and H13 as essential amino acids. Also by
studying Y10 as an endogenous peroxidase substrate for A-heme complexes, ratio-specific effects were observed, showing
an optimal dityrosine formation at an about 40-fold peptide excess. As dityrosine formation promotes A fibrillation while
free heme disturbs protein aggregation, we also investigated the effect of A-heme complex-derived peroxidase activity on
the formation of A fibrils. The fluorescence measurements showed a different fibrillation behavior at strong peroxidase
activity, leading also to altered fibril morphologies. The latter was detected by electron microscopy. As illustrated by selected
in vivo measurements on a mouse model of AD, the disease is also characterized by A-derived microvessel destructions and
hemolytic processes. Thus, thrombo-hemorrhagic events are discussed as a source for free heme in brain tissue. In summary,
we suggest the formation and enzymatic activity of A-heme complexes as pathological key features of AD.
Keywords: Alzheimer’s disease, A-heme complexes, amyloid- fibrillation, amyloid- toxicity, free heme, hemolysis,
peroxidase activity
INTRODUCTION
Alzheimer’s disease (AD) is the most common
chronic neurodegenerative disease and accounts for
about 72% of all elderly patients with cognitive
impairment and other symptoms of dementia [1, 2].
The progressive memory deficits and behavioral
changes [3] lead to increasing self-care problems of
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patients, making AD a major public health problem
in Western countries [4, 5]. While the incidence of
the disease is clearly associated with increasing age
[6, 7], the etiology of sporadic AD, by far the most
common form of the disease [8], is still not known
[9, 10].
The deposition of the amyloid- protein precur-
sor (APP)-derived peptide amyloid- (A) as fibrils
was originally regarded mainly as a hallmark for the
postmortem identification of the disease [11, 12].
Yet as A deposition is an early event during AD
pathology [7], the peptide is believed to essentially
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contribute to the neurodegenerative processes [7].
This is clearly illustrated by the fact that point muta-
tions (familial AD) or duplications (Down syndrome)
of APP, which lead to increased A formation,
cause an early onset of the disease [13]. Animal
experiments on the transmissibility of the disease by
A further prove an essential role of the peptide at
AD [14].
Biomarkers like oxidized neurotransmitter
[15, 16], lipid peroxides [16], and oxidative stress-
induced neuron degeneration [16] also suggest a
contribution of oxidative processes and reactive
oxygen species (ROS) to the AD pathology [17–19].
Yet again the exact mechanisms, e.g., reasons for
the elevated ROS formation in the brain of AD
patients, are not known [16]. A is one major target
for oxidation during AD [16], leading, for example,
to the formation of neurotoxic dityrosine [19–21].
Thereby a mutual promotion of the oxidative activity
and A-derived neurotoxicity seems to exist at AD
[16]. In fact, studies on a mouse model of the disease
show a local correlation between A-derived plaque
and ROS formation, suggesting A not only as a
target but also as a major source for the elevated
oxidative processes at AD [22].
Over 10 years ago, Atamna et al. showed that free
heme interacts with A, leading to the formation
of A-heme complexes, which exhibit a peroxidase
activity in the presence of H2O2 [23, 24]. The com-
plexes were found to contribute to neurotransmitter
degeneration in the brains of patients with AD [19,
20, 24]. Thus, the peroxidase activity of A-heme
complexes may provide a new explanation for the role
of both A and ROS in the pathology of AD. Sub-
sequent studies showed that this peroxidase activity
depends on the binding of free heme to histidine (most
likely H13) of A while R5 and Y10 are essential
for the subsequent peroxidase activity [19, 25, 26].
Most notably, R5, Y10, and H13 are the only amino
acids mutated in murine A (G5, F10, R13) [20].
Accordingly, mice show a weaker affinity for free
heme [2, 26] and exhibit a lower peroxidase activity
of A-heme complexes [19, 26, 27]. These differ-
ences may explain the lack of AD-like neuropathy in
these animals despite A fibril formation [19, 20].
The peroxidase activity of A-heme complexes also
leads to peptide dimerization via dityrosine formation
(Y10), which promotes A fibrillation at AD [19, 28,
29]. Yet there are also reports about a delayed A fib-
rillation after oxidation [21]. Moreover, free heme is
well known to inhibit A aggregation [19, 30, 31].
This dismantling effect of free heme on A fibrils
[25] may depend on the interaction of the heme group
with the hydrophobic part of the peptide (F19, F20)
[26, 32]. Thus, the influence of A-heme complex-
derived peroxidase activity on the plaque formation
in AD is still not clear.
In the current study, we carefully reinvestigated the
peroxidase activity of A-heme complexes, thereby
focusing on aspects not considered before. By apply-
ing non-aggregating A1-16 [25], we observed higher
enzymatic activities with increasing peptide-heme
ratios as well as at higher H2O2 concentrations and
decreasing pH values. By performing mutational
studies, we also systematically tested the influence
of the peptide sequence on the peroxidase activity
of A-heme complexes, showing the importance of
the human-specific amino acids R5, Y10, and H13.
Furthermore, the named tyrosine residue was con-
firmed to represent a major endogenous substrate for
the peroxidase activity of A-heme complexes.
Dityrosine may promote the A fibrillation [21]
while free heme has an inhibitory effect on the for-
mation of the peptide fibrils [33]. Thus, we also
investigated the effect of H2O2 and/or free heme
on the fibrillation of A1-40. These studies showed
delayed fibrillation kinetics of the peptide in the
presence of peroxidase components, which means
a prolonged existence of potentially neurotoxic A
oligomers [21, 34].
Finally, we also performed in vivo studies on
a mouse model for AD, thereby focusing on A-
derived blood flow alterations and the deposition of
the peptide at cerebral vessel walls. Further investi-
gations showed the co-localization of A and free
iron in the brain tissue of Tg2576 mice. Based
on these results we suggest A-derived microhem-
orrhages (cerebral amyloid angiopathy, CAA) and
hemolytic events induced by this peptide as poten-
tial mechanisms for the accumulation of free heme
in the brain tissue of AD patients. Accordingly,
A-heme complexes are discussed as possible key




Most experiments were performed in 10 mM
phosphate buffered saline (PBS, Sigma-Aldrich,
Steinheim, Deutschland), pH 7.4. For measurements
at pH 6.5 a citrate-phosphate buffer (CPB) prepared
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from 10 mM citrate (Merck, Darmstadt, Germany),
20 mM disodium hydrogen phosphate, and 140 mM
NaCl (both Sigma-Aldrich, Steinheim, Germany)
was used. Hemin (chloride salt of ferric protopor-
phyrin IX, Sigma Aldrich, Steinheim, Germany) as
a model for free heme was freshly prepared on a
daily basis as a 10 mM stock solution in 0.1 M
NaOH [24, 35].
A with the human-specific sequence was
obtained from Rockland, Limerick, PA, USA
(A1-16) or AlexoTech, Umeå, Sweden (A1-40).
Selected mutants and the rodent variant of A1-16
were synthesized in the Core unit DNA technolo-
gies of the IZKF Leipzig (Interdisziplinäres Zentrum
für Klinische Forschung, Interdisciplinary Center
for Clinical Research), Medical Faculty, Univer-
sity Leipzig, Leipzig, Germany. Stock solutions
(500 M) of A were prepared in PBS (A1-16) or
10 mM borax buffer, pH 9.0 (A1-40) and stored at
–20◦C until usage. The latter buffer was prepared by
supplementing sodium borate (Sigma-Aldrich, Stein-
heim, Germany) with 140 mM NaCl and adjusting the
pH value with 0.1 mM NaOH (Honeywell, Seelze,
Germany).
Peroxidase activity
The peroxidase activity of A-heme com-
plexes was quantified by performing 2,2′-azino-bis
(3-ethylbenzothiazoline-6-sulfonic acid)- (ABTS-)
based absorbance measurements [19, 36] in a plate
reader (TECAN Infinite M200, Männedorf, Switzer-
land): Briefly, the non-aggregating A1-16 [25]
(1–160 M) was pre-incubated for 5 min [37] with
hemin (1–10 M) and ABTS (1 mM, Sigma-Aldrich,
Steinheim, Germany) in PBS (pH 7.4) or CPB (pH
6.5) at 37◦C by using 96-well plates. After H2O2
(Sigma-Aldrich, Steinheim, Germany) addition (usu-
ally 500 M) via an injector device the formation of
ABTS radical cations (ABTS•+) was followed spec-
troscopically at 734 nm (734 = 1.5 × 104 M−1 cm−1)
[36, 38] for up to 90 min. All given concentrations
are final ones. From the observed initial slope of
the absorbance increase the peroxidase activity was
determined and expressed as mU/ml [39].
The H2O2 stock solution used for the initia-
tion of the peroxidase activity was freshly prepared
from a 30 % stock solution by diluting in bi-
distilled H2O, determined spectroscopically at 230
and 240 nm (240 = 74 M−1 cm−1, 230 = 43.6 M−1
cm−1) and stored at 4◦C till injection [40, 41].
In some experiments, instead of H2O2 injection a
glucose/glucose oxidase-system (G/GO-system) was
applied for a constant hydrogen peroxide generation.
Thereby 10 mM glucose and 2–200 mU/ml GO were
used to realize different H2O2 production rates.
Dityrosine formation
The peroxidase activity of A-heme complexes
was also measured by following the formation of
dityrosine bridges from the human-specific Y10
residue [25]. Briefly, 100 M of the A1-16 pep-
tide were pre-incubated with hemin (0.1–100 M)
at 37◦C. After H2O2 injection (usually 500 M)
the formation of dityrosine was followed for up to
90 min via fluorescence measurements (excitation:
320 nm, emission: 410 nm) [19, 21, 42] by using the
TECAN plate reader. Again in some experiments, the
G/GO-system was used instead of H2O2 injection.
Moreover, in selected samples 1 M horseradish per-
oxidase (HRP, Sigma-Aldrich, Steinheim, Germany)
was added instead of hemin [21].
The formation of dityrosine due to the peroxi-
dase activity of A-heme complexes was also verified
by using matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry.
Briefly, 100 M A1-16 were incubated with up to
2 M hemin or 1 M HRP. Then 100 M H2O2
were added and the samples were incubated for 20 h
at 37◦C. Afterwards 4 M hemopexin (Hpx) was
applied to bind hemin. The samples were subse-
quently centrifuged through a filter with 30 kDa
cut-off to remove both Hpx-hemin complexes and
HRP. Then 0.5 M 2,5-dihydroxybenzoic acid (DHB,
Sigma-Aldrich, Steinheim, Germany) in methanol
supplied with 0.1% trifluoracetic acid (TFA, Sigma-
Aldrich, Steinheim, Germany) was added as a matrix
and the samples were analyzed in in the positive
mode of a Bruker Autoflex (Bruker Daltonics GmbH,
Leipzig, Germany) mass spectrometer equipped with
a 337 nm nitrogen laser [43].
Amyloid-β fibrillation
The aggregation of A1-40 was followed by
using Thioflavin T (ThT, Sigma-Aldrich, Steinheim,
Germany) [44]. Briefly, the integration of ThT into the
peptide fibrils was followed for about 72 h at 37◦C by
performing fluorescence measurements (excitation:
440 nm, emission: 485 nm) [32, 44] in the TECAN
plate reader. While 50 M A and 20 M ThT were
used throughout [45], in selected experiments heme
(up to 10 M), HRP (1 M) and/or H2O2 (500 M)
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were added. The peptide was pre-incubated with
heme, HRP, and/or H2O2 for 4 h at 37◦C. Afterwards
ThT was added and the formation of A fibrils was
followed at 37◦C for up to 96 h. Thereby the fluores-
cence intensities of the samples were measured every
30 min after shaking the 96-well plate for 10 s.
For each condition the obtained values were cor-
rected for the fluorescence intensities observed in
the absence of A1-40 [45]. By fitting the curves
to a sigmoidal function (equation 1) the fibrillation
half-time (t1/2, corresponds to h) and the apparent fib-
rillation rate constant (kobs, corresponds to 1/τ) were
determined [32, 46, 47]. If no sigmoidal fitting was
possible a hyperbolic fitting function (equation 2) was
applied to determine t1/2 and kobs.







1 + e x−hτ
+ F2 + m2x (2)
The formation of A fibrils was verified by using
scanning transmission electron microscopy (STEM)
[31, 32]. Briefly, 10 d after the ThT measurements
1 l of selected samples were applied on formvar
coated copper grids, dried for 2 h and negatively
stained with 1% uranyl acetate [14]. STEM was
performed on a Zeiss SIGMA electron microscope
(Zeiss, Jena, Germany) equipped with a STEM detec-
tor and ATLAS software. From the STEM pictures
the morphology was analyzed [11].
In vivo measurements
For the in vivo investigation, Tg2576 mice, which
contain human APP with the Swedish double muta-
tion (K670N, M671L) under control of a hamster
prion protein promoter [48], were used. Age-matched
(18 months) non-transgenic littermates served as con-
trol mice. All animal experiments were conducted at
Leiden University after being approved by the Institu-
tional Animal Care and Use Committee in accordance
with the NIH Guide for the care and use of laboratory
animals.
Magnetic resonance angiography (MRA) mea-
surements were conducted on a vertical wide-bore
17.6 T Bruker spectrometer (Bruker BioSpin GmbH,
Rheinstetten, Germany) with a 1000 mTm−1 actively
shielded imaging gradient insert. A birdcage radio-
frequency coil with an inner diameter of 2 cm
was used. The system was interfaced to a PC
running Topspin 2.0 and Paravision 5.0 software.
Time-of-flight angiograms were obtained by using a
three-dimensional gradient-echo sequence and gen-
eration of maximum-intensity projections [49].
Histological analysis for the identification of A
deposits, CAA and iron was performed as described
previously [49, 50]: First, mice were anesthetized and
transcardially perfused with PBS, pH 7.4, followed
by 4% buffered paraformaldehyde (ThermoShandon,
Runcorn, UK) through the left cardiac ventricle.
Afterwards the brain was dissected out, placed in the
same fixative for 48 h, dehydrated, and embedded in
paraffin. Subsequently 5 m coronal sections were
cut using a vibratome.
To detect A, brain sections were subjected to
immunohistochemistry using anti-A (6E10) or anti-
A1-40 (BC40) antibodies. Immuno-labeling was
visualized by using the Vectastain ABC kit (Vector
laboratories, Bulingame, UK) according to the man-
ufacturer’s instructions. A-associated redox-active
iron was detected histochemically as described pre-
viously [51, 52]. Briefly, the brain sections were
incubated in 7% potassium ferrocyanide in 3% HCl
solution for 15 h and subsequently incubated in
3.5 mM 3,3’-diaminobenzidine (DAB) and 4.4 mM
H2O2 for 10 min. Images of the histological sections
were obtained using a Leica DM RE HC micro-
scope, interfaced to a Leica DC500 3CCD digital
camera (both Leica Microsystems GmbH, Wetzlar,
Germany).
Statistics
All ABTS-based kinetic measurements were per-
formed in triplicate. The peroxidase activity was
calculated from the initial slope of the averaged
kinetic curve whereby the given standard deviations
correspond to the coefficient of determination for
the applied linear curve fit. Also the fluorescence
measurements for the determination of dityrosine
formation were performed in triplicate and an aver-
age curve was created. From the stable fluorescence
plateau, the amount of dityrosine was determined
whereby the given standard deviation corresponds to
the oscillations of the fluorescence values within this
time frame. The MALDI-TOF measurements for the
verification of dityrosine were performed in triplicate
and mean and standard deviation of the relative peak
intensities were calculated.
For the aggregation measurements with ThT, again
at least three independent experiments were per-
formed. The obtained kinetic curves were averaged,
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corrected, and fitted to a sigmoidal or hyperbolic
curve to determine t1/2 and kobs. The standard devi-
ation given for these values corresponds to the
coefficient of determination obtained during the curve
fit. The average fibril diameter was determined by
analyzing the microscopic pictures. Thereby in each
sample ten randomly chosen fibrils were measured
to calculate mean and standard deviation of the fibril
diameter.
For all results, significant differences were deter-
mined by using a Student’s two tailed t-test after
verifying the Gaussian distribution of the data
(Shapiro-Wilk test). Thereby weakly significant
(*p ≤ 0.05), significant (**p ≤ 0.01), or strongly sig-
nificant (***p ≤ 0.001) differences were determined.
The presented results from the MRA measure-
ments and the microscopic analysis of the brain
sections are representative examples obtained during
the analysis of multiple measurements. Five Tg2576
and five control mice were used for the in vivo
studies.
RESULTS
Heme peroxidase activity promotion by Aβ
Using ABTS-based kinetic measurements with
A1-16 we observed a clear enhancement of the
heme-derived peroxidase activity in the presence of
the peptide. Furthermore, the peroxidase activity of
A-heme complexes showed a characteristic pH-
and H2O2-dependence. As illustrated by the rep-
resentative kinetic curves shown in Fig. 1A, while
free heme (10 M, grey dashed line) led only to a
minor and slow formation of ABTS•−, in the pres-
ence of increasing A concentrations (10–180 M,
grey - black lines) constantly elevating ABTS oxi-
dation rates were observed. In fact, as shown in
Fig. 1B in the presence of 2 M peptide already
a strongly significant elevated peroxidase activity
(1.18 ± 0.01 mU/ml) was observed as compared to
the heme control (1.03 ± 0.01 mU/ml). With increas-
ing A-heme ratio an almost linear increase in the
Fig. 1. A-derived acceleration of heme-dependent peroxidase activity. 10 M heme and up to 180 M A1-16 (A and B) or 1 M heme and
up to 100 M A1-16 (C) were pre-incubated in PBS in the presence of ABTS. After H2O2 addition (500 M), the formation of ABTS•− was
followed spectroscopically. While in (A) kinetic samples for 10 M heme alone (grey, dashed) or in the presence of 10 M, 60 M, 120 M,
or 180 M peptide (grey to black lines) are shown, in (B) the peroxidase activity calculated from the initial slopes is plotted against the
A-heme ratio. The corresponding data for 1 M heme and up to 100 M A are displayed in (C). In (D) the relative A-derived promotion
of the heme-dependent peroxidase activity is shown for both conditions.
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Fig. 2. Effect of A on the H2O2-dependent heme peroxidase activity. In (A) 1 M heme and up to 100 M A1-16 were pre-incubated in
PBS in the presence of ABTS and 2 mU/ml (light grey), 20 mU/ml (grey) or 200 mU/ml GO (black). After addition of 10 mM glucose the
formation of ABTS•− was followed and the initial peroxidase activity determined. In (B) for 10 M heme (squares) or 1 M heme/10 M
A1-16 (circles) the ABTS oxidation was followed after addition of 20–5000 M H2O2. The calculated initial peroxidase activities were
related to the particular values observed at 20 M H2O2.
peroxidase activity was observed with the highest
value (11.89 ± 0.18 mU/ml) at 18-fold peptide excess
over heme. Yet as illustrated by the data obtained from
measurements with 1 M heme (peroxidase activ-
ity: 0.13 ± 0.00 mU/ml) and up to 100 M peptide
(Fig. 1C) at even higher A-heme ratios a satu-
rating effect can be observed. In the absence of
heme, the peptide exhibited no peroxidase activity
(not shown).
Most interestingly, by plotting the relative increase
in the peroxidase activity (referred to the value
obtained in the sole presence of heme) against the A-
heme ratio (Fig. 1D) for the experiments with 10 M
heme (black), an approximate 12-fold increase in the
peroxidase activity was already observed at an 18-
fold peptide excess. In contrast, by using 1 M heme
(grey), a comparable effect was only observed in the
presence of a 100-fold peptide excess. At a 10-fold
excess of A1-16, a 7.8-fold higher peroxidase activ-
ity was found for 10 M heme while with 1 M heme,
a 10-fold peptide excess led only to an about 2.9-fold
higher peroxidase activity.
As shown in Supplementary Figure 1, we also
performed measurements at pH 6.5. As illustrated
by the displayed selected kinetic curves (Supple-
mentary Figure 1A) and proofed by determining the
corresponding activities the peroxidase activity of
10 M heme (1.96 ± 0.09 mU/ml) was already about
90% higher as compared to the value observed at
pH 7.4. Also upon application of increasing peptide
concentrations (Supplementary Figure 1B), higher
peroxidase activities were observed at pH 6.5 (black)
than at pH 7.4 (white). Yet the peptide-dependent pro-
motion of the heme-derived peroxidase activity was
not completely equal for both pH values: While at
pH 7.4, an 18-fold peptide excess led to an almost
12-fold increase in the peroxidase activity (see also
Fig. 1D); at pH 6.5, a A-heme ratio of 18:1 led only
to an about 7.8-fold higher ABTS•− formation rate.
Instead of a H2O2 bolus addition, we used the
glucose/glucose oxidase-system (G/GO-system) in
selected experiments in order to create a constant
hydrogen peroxide production during the peroxi-
dase measurements. As shown in Fig. 2A, for all
applied GO concentrations (2–200 mU/ml) again a
clear A-heme ratio-dependent increase in the perox-
idase formation rate was observed. Thereby a minor
H2O2 dependence can be observed: At 200 mU/ml
GO (black) an A-heme ratio of 100/1 instead of 1/1
led to an about 7.0-fold higher peroxidase activity.
However, by using 20 mU/ml (grey) or 2 mU/ml (light
grey) GO, a comparison of the named A-heme ratios
showed only an about 3.7-fold or 3.2-fold increase
in the ABTS•− production rate. As calculated from
a calibration curve (Supplementary Figure 2), the
used amount of GO yields to a constant produc-
tion of 2.62 M, 25.69 M, or 159.05 M H2O2/min,
respectively, which meets the expected H2O2 produc-
tion rates.
Yet, as illustrated in Fig. 2B, by incubating either
10 M heme (squares) or 10 M A and 1 M heme
(circles) with increasing H2O2 concentrations the
increase in the relative peroxidase activity (refer-
enced to the values obtained at 20 M H2O2) was
almost equal: For instance, the application of 500 M
H2O2 led to an 11.3-fold higher activity in the case
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of the A-heme complex while for heme alone a 9.1-
fold increase was observed. These results proof again
the heme-based enzymatic activity of A-heme com-
plexes. Still, again a minor effect of the peptide on
the H2O2 concentration-dependent promotion of the
heme-derived peroxidase activity may be guessed.
Aβ sequence-dependent heme peroxidase activity
promotion
Next we tested the relevance of the human-specific
amino acid sequence of A for the promotion of
the heme-dependent peroxidase activity by incubat-
ing 10 M heme with a 10-fold excess of different
A peptides. Thereby we focused on sequence dif-
ferences between the human and rodent peptide, but
also included selected mutants described in the lit-
erature. The results clearly show that the enzymatic
activity of A-heme complexes strongly depends on
the human-specific sequence of the peptide.
As illustrated by the representative kinetic curves
in Fig. 3A, the exchange of one of the three human-
specific amino acids of A1-16 (R5, Y10, H13) to the
rodent equivalent (G5, F10, R13) already led to con-
siderably lower curves in comparison to the human
peptide (black line). Yet the ABTS•− formation of
these single mutants (dark grey lines) seems to be still
stronger in comparison to the mouse peptide (light
grey line) and certainly stronger than the peroxidase
activity of heme alone (light grey dashed line). As
shown by the exemplary curves in Fig. 3B, the corre-
sponding double mutants (R5G, H13R; R5G, Y10F;
Y10F, H13R) (grey lines) apparently showed an even
lower peroxidase activity than the single mutants that
was, however, still higher than the ABTS oxidation
rate of the mouse peptide (light grey line). As both
the human and the rodent A peptide contain a his-
tidine at position 14, an artificial double mutant was
also included where both the human-specific H13 and
H14 were replaced by glycine. This double mutant
seemed to show an even lower peroxidase activity
than the mouse peptide, which was, however, still
stronger than the value observed for heme alone (light
grey dashed line).
In Fig. 3C, the peroxidase activity for all samples
determined from the initial slope is shown. While
for heme alone, a peroxidase activity of 1.03 ± 0.01
mU/ml was found, the peroxidase activity in the pres-
ence of a 10-fold excess of human A was about
8-fold higher (7.99 ± 0.27 mU/ml). In contrast by
using rodent A, only an about 2.5-fold higher value
(2.49 ± 0.01 mU/ml) was observed. Upon mutation
of one of the human-specific amino acids in A1-16
with the rodent equivalent significant (R5G) or highly
significant (Y10F, H13R) lower peroxidase activities
were observed as compared to the human peptide.
By using single mutants described in the litera-
ture (R5N, Y10G, H13A), again a highly significant
reduction of the A-mediated promotion of the heme-
dependent peroxidase activity was found. In fact, the
effect of these single mutants was always stronger
as compared to the corresponding rodent mutations
(see, for example, Y10F and Y10G). However, all
tested single mutants still led to a strongly signifi-
cant higher peroxidase activity than the rodent A
peptide.
The peptides where two of the three human-
specific amino acids were replaced by the rodent
equivalents (R5G, Y10F; R5G, H13R; Y10F, H13R)
had even lower promoting effects on the heme-
derived peroxidase activity. Still the obtained values
were strongly significant higher than by using the
rodent peptide. Since both in the human and the
rodent A sequence a histidine residue is present at
position 14 of the peptide, we guessed that a mutation
of the human-specific histidine 13 might be counter-
balanced by H14. In fact, by applying a corresponding
double mutant (H13G, H14G), the obtained per-
oxidase activity (2.06 ± 0.03 mU/ml) was strongly
significantly lower than for the rodent peptide. All
tested peptides exhibited no peroxidase activity in the
absence of heme (not shown).
Y10 as an endogenous peroxidase substrate
of Aβ-heme complexes
By measuring the formation of dityrosine bridges,
the human-specific Y10 in the human peptide was
found as an important endogenous substrate for the
peroxidase activity of A-heme complexes. Thereby
the efficiency of dityrosine formation depended on
the A-heme ratio, the H2O2 concentration, and the
A sequence. The peroxidase-derived formation of
human A dimers due to Y10-dependent dityrosine
formation was also verified by MALDI-TOF mass
spectrometry.
In Fig. 4A representative kinetic curves illus-
trate the fluorescence increase at 410 nm (excitation:
320 nm) after the addition of 500 M H2O2 to
100 M A1-16 in the presence of different heme
concentrations. While at an A-heme ratio of
10:1 (10 M heme, black), almost no fluorescence
increase was observed; at 2.25 M heme (grey, A-
heme ratio: 44.4:1), a fast and strong increase in the
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Fig. 3. A sequence-dependent acceleration of the heme-derived peroxidase activity. 10 M heme alone or in the presence of 100 M A
were pre-incubated in PBS in the presence of ABTS. After H2O2 addition (500 M) the formation of ABTS•− was followed spectroscopically.
Both in (A) and (B) kinetic sample spectra for heme alone (light grey, dashed) or in the presence of the human (black line) or the rodent (grey
line) peptide are shown. Also kinetic examples for peptides with one (A) or two (B) mutations of the human-specific amino acids R5, Y10,
and H13 are included. In (C) for all tested peptides the peroxidase activity calculated from the initial ABTS•−-derived absorbance increase
are shown. Thereby also values obtained for single mutants of human A1-16 described in the literature are included.
fluorescence at 410 nm took place, indicating a quick
formation of dityrosine bridges. However, at even
higher A-heme ratios (e.g., 200:1, light grey), again
lower fluorescence values were observed, showing a
lower yield of dityrosine. In the sole presence of the
peptide (dashed line), no dityrosine formation took
place.
By using the data obtained from control measure-
ments with HRP (not shown), the displayed maximal
fluorescence values at 410 nm were translated to the
amount of dityrosine formed after H2O2 addition.
The corresponding data for the measurements in the
presence of 500 M H2O2 (black) and 100 M H2O2
(white) are shown in Fig. 4B. For 500 M H2O2,
starting at an A-heme ratio of 12.5:1 (corresponds
to 8 M heme) up to an A-heme ratio of 133.3:1
(0.75 M heme) significant higher fluorescence val-
ues as compared to the negative control (only peptide,
dashed line) were observed. Thereby the highest dity-
rosine formation was found at an A-heme ratio of
44.4:1. The determined 21.08 ± 2.02 M dityrosine
correspond to a relative yield of 42.2%, given the
application of 100 M peptide. In the presence of
100 M H2O2, a comparable ratio dependence was
observed. Under these conditions, the highest dity-
rosine formation was found at an A-heme ratio of
33.3:1 (13.37 ± 1.80 M, 26.7% relative yield).
As shown in Fig. 4C, by using 10 mM glucose
and glucose oxidase (black: 200 mU/ml, grey: 20
mU/ml, white: 2 mU/ml) as a H2O2-generating sys-
tem an optimal dityrosine formation was always
observed in the presence of 2.25 M heme, which
corresponds to an A-heme ratio of 44.4:1. More-
over, the results from the measurements with the
G/GO-system confirm the observation that in the
presence of more H2O2 higher dityrosine yields are
obtained although the values observed at 200 mU/ml
GO (10.30 ± 1.49 M, 20.6 % relative yield) and 2
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Fig. 4. Formation of dityrosine bridges due to heme-derived peroxidase activity. The formation of dityrosine was quantified by following the
increase in the fluorescence at 410 nm (excitation: 320 nm) after adding up to 500 M H2O2 to 100 M A1-16 in the presence of different
heme concentrations. As illustrated for 500 M H2O2 in (A) and quantified for 500 M (black) and 100 M (white) H2O2 in (B) at an
A-heme ratio of about 30-50:1 an optimal dityrosine formation was observed. Comparable results were obtained by using the G/GO-system
(C). Upon application of single and double mutants of human A1-16 (D) a dityrosine formation was never observed in the absence of Y10.
In the presence of the named amino acid a fairly comparable dityrosine formation rate was found for all tested peptides.
mU/ml GO (7.42 ± 1.21 M, 14.8% relative yield)
showed no significant difference.
We also tested the dityrosine formation from rodent
A as well as the single and double mutants of
human A mentioned before (see above) by incu-
bating the peptides (100 M) with 3 M heme in
the presence of 500 M H2O2. As illustrated by the
quantitative analysis of the obtained data (Fig. 4D),
all Y10-containing peptides showed a comparable
dityrosine formation. For the R5G mutant, weakly
significant higher final fluorescence values were seen,
while for H13R and H13A, significant higher final
fluorescence values were obtained, suggesting big-
ger dityrosine yields for theses peptides. In fact,
while the obtained fluorescence value for human
A1-16 at the given A-heme ratio (33.3:1) was
18.62 ± 1.39 M dityrosine, for H13R, an about 2-
fold higher yield (37.97 ± 6.99 M dityrosine) was
calculated. Most interestingly for the artificial his-
tidine double mutant (H13G, H14G), no significant
reduction in the dityrosine yield was observed despite
the strongly significant lower peroxidase activity
observed in the corresponding ABTS measurements
(see Fig. 3C). In striking contrast, in the absence of
Y10 (rodent A, Y10-single and -double mutants) no
dityrosine formation was observed at all, proving the
specificity of the fluorescence measurements.
The formation of dityrosine bridges in A1-16 due
to the peroxidase activity of A-heme complexes
was reconfirmed using MALDI-TOF mass spectrom-
etry (Supplementary Figure 3). As illustrated by the
representative spectra shown in Supplementary Fig-
ure 5A-C, in the absence of H2O2 (dashed lines)
only peaks at m/z 1956.0 (A + H+) followed by
a typical isotopic pattern were found, corresponding
to monomeric A1-16. In the absence of any further
additions (Supplementary Figure 3A), the incubation
of the peptide with 100 M H2O2 (straight line) did
not lead to any new peaks. The same holds for the
addition of H2O2 to 100 M peptide in the pres-
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ence of 1 M heme (Supplementary Figure 3B). In
contrast, upon incubation of A with H2O2 in the
presence of 2 M heme (Supplementary Figure 3C),
a new peak at m/z 3911.2 (A-A + H+) was found,
corresponding to dimeric A1-16 with a dityrosine
bridge. Again this new peak was followed by a
typical isotopic pattern. A much more prominent dity-
rosine formation was observed after incubation of
A1-16 with H2O2 and 1 M HRP (Fig. 5D). An
average relative dityrosine formation of 39.6 ± 9.0%
was observed in the HRP-containing sample while in
the presence of 2 M heme only about 3.1 ± 0.7%
was found, indicating a weak but still notable per-
oxidase activity in the latter case. Although not
visible in the given sample (Supplementary Fig-
ure 3D), the statistical analysis showed that in the
presence of HRP even in the absence of H2O2 (dashed
line) a small dityrosine formation (2.6 ± 1.4 %)
takes place.
Effect of peroxidase activity of Aβ-heme
complexes on Aβ fibrillation
The ThT-based fluorescence measurements sug-
gest inhibitory effects of free heme and H2O2 on the
fibrillation of A1-40. Moreover, upon co-incubation
of higher amounts of HRP or higher heme con-
centrations with H2O2, a totally different kinetics
of the fluorescence increase was observed, possibly
implicating a peroxidase-mediated change in the A
fibrillation behavior. However, as verified by STEM
in all samples, a formation of A fibrils took place
while differences in the morphology were clearly
observable.
As shown in Fig. 5A in the absence of further addi-
tions the incubation of A1-40 (50 M, black dashed
line) with ThT led to a typical sigmoidal increase in
the fluorescence with a fibrillation half-time (t1/2) of
51.60 ± 0.01 h and an apparent rate constant (kobs) of
Fig. 5. Effect of heme-derived peroxidase activity on the A fibrillation kinetics. A1-40 (50 M) was pre-incubated with free heme
(0.1–10 M, dark – light grey) or HRP (1 M, light grey, dashed) in the absence (A) or presence (B) of H2O2 (500 M) before adding
ThT (20 M). Without H2O2 (A) for the peptide alone (black, dashed), a t1/2 value of 49.58 ± 0.99 h and a kobs value of 0.99 ± 0.01 h−1
was observed while increasing heme concentrations constantly delayed and decreased the ThT-dependent fluorescence. In the presence of
1 M HRP, almost no fluorescence intensity increase was observed. Also H2O2 alone (B) inhibited the fluorescence increase while the
additional presence of free heme increased the effect. In the presence of H2O2 and 10 M heme or 1 M HRP, a slight (heme) or strong
(HRP) hyperbolic increase in the ThT-derived fluorescence was observed instead of a sigmoidal kinetics. In (C) and (D), the t1/2 and kobs
values are given for the experiments without (white) or with (black) H2O2 whereby sometimes a logistic curve fit (dashed) was applied.
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0.99 ± 0.01 h−1 (see also Supplementary Table 1).
Yet the curves observed after incubation with free
heme (0.1–10 M, dark grey – light grey lines) show
a continuous shift in the lag phase as well as lower
final fluorescence values, indicating a delay and par-
tial inhibition of the A fibrillation. In fact, in the
presence of 10 M heme, t1/2 and kobs values of
83.65 ± 2.71 h and 0.14 ± 0.01 h−1 were observed,
suggesting a delayed and impaired formation of A
fibrils. Most interestingly in the presence of HRP
(1 M, light grey dashed line), almost no increase
in the ThT-derived fluorescence was observed within
96 h, which may indicate an efficient inhibition of
the A fibrillation in the presence of the peroxidase.
A fibrillation half-time of 71.07 ± 0.66 h and a kobs
value of 0.37 ± 0.05 h−1 were determined under these
conditions.
As shown by the kinetic curves in Fig. 5B,
after pre-incubation of A1-40 with 500 M
H2O2 (50 M, black dashed line) the ThT-based
fluorescence measurements showed a delayed (t1/2:
73.96 ± 0.59 h) and slower (kobs: 0.13 ± 0.00 h−1)
increase in the fluorescence, indicating again a dis-
turbed fibrillation of the peptide. Upon co-incubation
of A with 500 M H2O2 and free heme (0.1–10 M,
dark grey – light grey lines), a further delay and
decrease in the fluorescence intensity increase was
observed. Of note, at 10 M heme a fitting of the
kinetic data to a sigmoidal curve was no longer possi-
ble. Instead a hyperbolic equation was applied, which
better meets the small initial fluorescence increase
observed under the described conditions. As shown
in Supplementary Table 1, in this sample the half-
maximal fluorescence intensity was achieved after
about 1.15 ± 5.33 h. Most interestingly also in the
presence of 500 M H2O2 and HRP (1 M, light
grey dashed line) an instant fluorescence increase was
observed. The curve fitting revealed a t1/2 value of
2.97 ± 1.42 h. Both half-times lay within the 4 h ThT-
free pre-incubation time of A1-40 with heme, HRP,
and/or H2O2.
In Fig. 5C, the t1/2 values of all samples are com-
pared whereby the white bars represent the H2O2-free
samples while in black the results obtained in the
presence of H2O2 are given. This representation
clearly shows the retarding effect of free heme, HRP,
and H2O2 on the A1-40 fibrillation as illustrated by
higher fibrillation half-times of the ThT-sigmoidal
fluorescence increase. In striking contrast, upon incu-
bation of the peptide with 500 M H2O2 and either
10 M heme or 1 M HRP a hyperbolic fluorescence
increase and considerably lower t1/2 values were
observed (dashed), suggesting different fibrillation
kinetics of A under these conditions. Maybe the
peroxidase activity of HRP/A-heme complexes is
responsible for these differences. In Fig. 5D, the cor-
responding kobs values are shown, clearly illustrating
the decelerating effect of free heme on the ThT-
derived fluorescence increase even in the absence of
H2O2. In the presence of H2O2, even slower values
were observed, which, however, increased slightly
at higher heme concentrations. In the presence of
500 M, H2O2 and either 10 M heme or 1 M
HRP a comparable kobs value was obtained from the
applied logistic curve fitting (dashed).
We also created STEM pictures of the described
samples to confirm the A fibrillation as well as
to study the long-term effect of free heme, HRP,
and H2O2 on the formation of peptide fibrils. As
illustrated by the representative microscopic pictures
given in Fig. 6, both in the absence (Fig. 6A-E) and
in the presence (Fig. 6F-J) of H2O2, an ultimate
formation of A fibrils was observed. Thereby an
average fibril diameter of 14.4 ± 2.3 nm was observed
throughout the samples. However, differences in
the fibril morphology and density were sometimes
clearly visible. While the presence of 0.1 M heme
(Fig. 6B, G) and/or 500 M H2O2 (Fig. 6F, G) seem
to have no effect on the fibrillation of 50 M A1-40
(A) in the presence of 1 M (Fig. 6 C, H) or 10 M
(Fig. 6D, I) heme, the formation of a more dense
A fibril network seems to take place. Thereby, more
amorphous fibrils were observable in the absence of
H2O2 (Fig. 6C, D), while in the presence of H2O2
(Fig. 6H-I), straight and dense fibrils were visible.
In the presence of HRP (Fig. 6E, J), again amor-
phous fibrils were observed in the absence of H2O2
(Fig. 6E), while in the presence of H2O2 (Fig. 6J),
straight and dense fibrils were visible. Yet in the lat-
ter case, much less fibril formation was observed as
compared to the heme-containing samples.
Determination of Aβ-derived cerebral
angiopathies in vivo
The MRA measurements clearly showed a
decreased blood flow in the middle cerebral artery
(MCA) in the Tg2576 mice, correlating well with
the increased perivascular deposition of A in this
AD model. Moreover, a co-localization of the pep-
tide with free iron was observed in the brain tissue of
the animals.
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Fig. 6. A fibril formation in the presence of peroxidase components. A1-40 (50 M) was pre-incubated with 0 M (A, F) – 10 M heme
(D, I) or 1 M HRP (E, J) either in the absence (A-E) or presence (F-J) of 500 M H2O2. After 4 h, ThT (20 M) was added for the kinetic
measurements given in Fig. 5. The shown representative STEM pictures were taken from samples prepared about 10 days after the ThT
measurements. In all samples, A fibrils with an average diameter of 14.4 ± 2.3 nm are clearly visible (see inserts) while differences in the
overall fibril structure morphology and density (see overview) were observed. Especially in the presence of higher heme concentrations, a
denser but more amorphous fibril network was observed in the absence of H2O2 (C-D) while in the presence of H2O2, the fibril network
resembled the negative control (A, neither heme nor H2O2). In the sample containing HRP and H2O2 (J), a less and shorter fibrils were
observed. The scaling bars correspond to 500 nm (overview) and 250 nm (inserts).
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Fig. 7. Blood flow disturbances and co-localization of A and iron in Tg2576 mice. MRA measurements were performed for the visualization
of the blood vessels while CAA, A deposits, and iron accumulation were detected via staining of the brain sections. While the angiogram
of an 18-month-old healthy control animal (A) showed no blood flow alterations, in the corresponding picture of a Tg2576 mouse (B) blood
flow defects are clearly visible (arrow). As shown in (C), the latter correspond with a marked deposition of A1-40 (arrow) in the pial branches
of the MCA. Moreover, in the Tg2576 mice a co-localization of A plaques (D) and iron (E) in the adjacent brain sections was observed
(small arrows). The inserts given in (D-E) represent an about 8-fold magnification of the regions marked with the red arrows. The scaling
bars correspond to 500 m (C) and 50 m (D-E).
As A is responsible both for microhemorrhages
[53] and for erythrocyte alterations [54] in AD, we
finally performed in vivo measurements to illustrate
a possible pathway for the formation of A-heme
complexes at AD. As illustrated in Fig. 7A-B, the
MRA studies showed a marked disturbance of the
blood flow in the branches of the MCA of Tg2576
mice (Fig. 7B), while in the healthy control (Fig. 7A)
normal signal intensities were observed throughout
the vessels. In both cases, a sagittal view of the head
of age-matched (18 months) animals is shown. The
identification of cerebral arteries was performed by
inspecting the angiograms under various angles and
comparing the vessels to literature data [49, 55–57].
As illustrated by the microscopic picture given
in Fig. 7C, the blood flow disturbances in the AD
model animals coincide with the massive deposi-
tion of A1-40 in the territory of the pial branches
of the MCA. In the healthy control animals, no
accumulation of the peptide in the vessel walls was
observable (not shown). Furthermore, the analysis
of adjacent brain sections showed a coincidence of
amyloid plaques (Fig. 7D) with the deposition of
free iron (Fig. 7E) in the Tg2576 mice. These results
leave open the possibility that the iron could be the
leftover of free heme, which, considering the CAA
shown in Fig. 7A-C, may result from microhemor-
rhages and hemolytic events in the brain tissue of AD
patients. In summary, the detected A-derived blood
flow alterations and the co-localization of free iron
with A plaques may indicate the transient formation
of A-heme complexes during the pathology
of AD.
DISCUSSION
The applied system is suitable to test the
peroxidase activity of Aβ-heme complexes
In this study, ABTS-based absorbance measure-
ments were used as a well-established method to
study the peroxidase activity of A-heme com-
plexes [19]. Thereby we followed the ABTS•+
formation at 734 nm to avoid interferences from other
assay components [36] including free heme [58, 59].
Furthermore, most experiments were conducted at an
excess of ABTS to avoid over-oxidation to ABTS2+
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and related side products [60]. The small absorbance
decrease observed at longer measuring times may be
attributed to ABTS backformation [60]. It was mainly
observed in the presence of tyrosine-containing A
sequences, suggesting a radical transfer to the pep-
tide. The measurements with free heme in the absence
of A yielded activities of 0.13 mU/ml (1 M heme)
and 1.03 mU/ml (10 M heme), respectively, proving
an adequate correlation between the concentration of
the peroxidase-active component and the determined
initial enzymatic activity.
Aβ promotes the peroxidase activity of free heme
in a concentration-dependent way
The ABTS measurements clearly showed that A
promotes the peroxidase activity of free heme in a
concentration-dependent manner. Thereby at ratios
higher than 20:1 a saturating effect was observed,
maybe indicating the formation of A-heme com-
plex with the named stoichiometry. Comparable
results were also observed in other studies whereby,
however, only ratios up to 8:1 were applied [19,
27, 61]. In line with others in the absence of free
heme, we observed no peroxidase activity [25], prov-
ing a heme-based enzymatic activity of A-heme
complexes.
The relative effect of A on the heme-derived
peroxidase activity also depended on the absolute
heme concentration: At higher heme concentrations,
stronger effects of the peptide were observed. These
results indicate the formation of A-heme complexes
with multiple heme units. Moreover, they suggest a
non-linear increase in the peroxidase activity upon
cerebral accumulation of free heme, especially in
the presence of elevated A levels observed in AD
patients.
Another new aspect addressed in this study is
the H2O2 dependence of the A-heme complex-
mediated peroxidase activity. Thereby either H2O2
was directly applied or the G/GO-system was used,
which allows a continuous H2O2 production [62].
A direct comparison of the H2O2 concentration-
dependent increase in the relative peroxidase activity
yielded comparable effects for free heme (10 M)
and for A-heme complexes (10 M/1 M), again
proving a heme-based peroxidase activity of the com-
plexes. Still at higher constant H2O2 production
rates, a stronger promotion of the enzymatic activ-
ity with increasing A concentrations was observed,
which may indicate a coordinating effect of the pep-
tide with regard to the heme activation by H2O2.
In fact, in chordata heme peroxidases, the amino
acids on the distal heme site are known to regu-
late the access of H2O2 toward the heme center
[63, 64].
Selected studies at pH 6.5 showed higher peroxi-
dase activities of A-heme complexes as compared
to the values obtained at pH 7.4. While the
pH-dependent peroxidase activity of A-heme com-
plexes was never tested before, these results are well
in line with the results obtained with heme peroxi-
dases [63, 64]. The studies also revealed an influence
of the pH value on the A-derived promotion of the
peroxidase activity, showing a stronger effect of the
peptide at neutral conditions. These results can be
explained by the fact that both, the binding of the
peptide to heme [27] and the subsequent promotion
of the heme-mediated peroxidase activity are influ-
enced by the pH value [25, 35]: While for the binding
of the heme a histidine residue (most likely H13)
with a neutral net charge is responsible [19, 33, 65],
an acidic arginine (R5) promotes the stabilization of
H2O2 as the sixth heme ligand [20] and its subsequent
homolytic cleavage [15, 19, 27]. Y10 is regarded as
the second amino acid contributing to the peroxidase
activity of A-heme complexes [15, 25].
As up to low micromolar heme concentration were
found in the brain tissue of AD patients, the per-
formed peroxidase activity measurements (1/10 M
heme) are somewhat comparable to the physiologi-
cal conditions [28]. Yet the applied A concentrations
(up to 100 M) are far beyond the physiological range
[66, 67]. Still such high peptide concentrations were
necessary to explore the A-heme ratio-dependent
peroxidase activity. Moreover, the aggregation of A
as well as its deposition around blood microvessels
[53, 68] may lead to high local concentrations of
the peptide, especially at places of hemolysis-derived
formation of free heme. Regarding H2O2 again
unphysiological high concentrations were applied.
Still the lowest concentration used in our studies
(20 M, see Fig. 2B) approximately meet (patho-)
physiological H2O2 concentrations in the blood [69].
In contrast, by using 500 M H2O2, a suitable high
peroxidase activity could be observed to investigate,
e.g., the A sequence-dependent enzymatic activity
of A-heme complexes.
The three amino acids responsible for the binding
(H13) of free heme and the subsequent peroxidase
activity of A-heme complexes in the presence of
H2O2 (R5, Y10) resemble the corresponding struc-
tures in chordata heme peroxidases [19, 27, 70].
Moreover, theyrepresent theonlydifferencesbetween
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the human and the mouse sequence of the peptide
[19, 20]. While we included only peroxidase activ-
ity experiments with A1-16 in the manuscript some
preliminary experiments as well as literature data [61]
clearly indicate a much higher peroxidase activity of
the long peptide in the presence of free heme.
Human Aβ has the strongest impact on
the peroxidase activity of free heme
We next tested the impact of the peptide sequence
of A1-16 on the promotion of the heme-mediated
peroxidase activity. Thereby special attention was
paid to the three amino acids mutated in the human
peptide (R5, Y10, H13) in comparison to the rodent
peptide (G5, F10, R13). Already published muta-
tional studies only cover a direct comparison between
human A and the rodent equivalent [27] or the
replacement of single human-specific A amino
acids by non-rodent equivalents, namely R5N, Y10G,
and H13A [19, 25]. Still the reported results are com-
parable to ours: While others also clearly showed
a lower peroxidase of A-heme complexes formed
with the rodent peptide as compared to complexes
formed with human A, the differences were not
quantified and only A-heme ratios up to 8:1 were
used [27]. In our studies, the rodent peptide only dou-
bled the peroxidase activity of free heme, while in the
presence of the human peptide, an about 8-fold higher
peroxidase activity was observed.
Regarding single mutants for Y10G a marked
decrease in the peroxidase activity was reported [25],
which corresponds to our results. In fact, in our stud-
ies Y10G turned out as the single mutant with the
strongest effect, suggesting Y10 as an important key
player during the peroxidase activity of A-heme
complexes. However, for the corresponding rodent
mutation (Y10F), only an about 1.4-fold decreased
peroxidase activity was observed. As suggested by a
recent publication, the named mutants influence the
structure of the peptide, which also affects the peroxi-
dase activity of the formed A-heme complexes [61].
Regarding the artificial mutation R5N, again a strong
decreasing effect on the peroxidase activity was
reported [19], which is only partially reflected by our
results. Again, the corresponding rodent single muta-
tion (R5G) had a weaker effect. These differences
may be attributed to varying experimental conditions,
including the applied A-heme ratio and H2O2 con-
centration. Another possible explanation comes from
a recently published review: As stated by Kohdarahmi
et al., R5 may have only a minor effect on the perox-
idase activity of A-heme complexes, most likely by
influencing the structure and/or aggregation behavior
of A [61].
For H13A (and H14A), almost no effect on the per-
oxidase activity was reported, which was attributed
to the fact that H13 (present in human A) can
be replaced by H14 (present in human and rodent
A), and vice versa, in regard to the binding of free
heme [19]. Accordingly for the H13G, H14G dou-
ble mutation, a peroxidase activity at the level of
free heme was observed [19]. Regarding the single
mutants, the results are only partially comparable to
ours where a single mutation of H13 (H13R or H13A)
already led to a considerably decreased peroxidase
activity. Yet in line with others [19], upon application
of the H13G, H14G double mutation, we observed a
massive reduction of the peroxidase activity. In fact,
the obtained value was even slightly lower than the
peroxidase activity obtained in the presence of free
heme and rodent A1-16. Yet unlike shown by others,
it still exceeded the peroxidase activity observed in
the sole presence of free heme [19].
As reported previously [61], for human A (see
Fig. 1), but not, for example, for the murine pep-
tide, increasing A-heme ratios lead to a considerable
increase in the peroxidase activity. Thus, the differ-
ences obtained by using a 10/1 ratio may be small by
applying equimolar A-heme complexes.
In summary, regarding the tested single mutants,
the replacement of Y10 showed the strongest effect,
while lower impacts were found for H13 und R5.
Yet considering that H13 may be replaced by
H14 [33], the strongest impact was found for his-
tidine (H13/H14), followed by the human-specific
residues Y10 and R5. In fact, H13/14 is responsi-
ble for the binding of free heme [26, 27, 65] while
Y10 and R5 contribute to the subsequent peroxidase
activity of A-heme complexes [19, 25]. Most inter-
estingly Y10 is not only regarded as a redox-active
center contributing to the peroxidase activity of A-
heme complexes [19] but also as an endogenous target
for this enzymatic activity, leading to the formation
dityrosine [21, 25, 29].
Human-specific Y10 is an endogenous
peroxidase substrate of Aβ-heme complexes
Our studies confirmed the results of others [21, 25]
that upon peroxidase activity of A-heme complexes
Y10 can be oxidized to form 1,3-dityrosine [42, 71].
Yet the impact of the A-heme ratio and the amount of
H2O2 on the dityrosine yield was never tested before.
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Our fluorescence measurements suggest an opti-
mal dityrosine formation at an A-heme ratio of
about 40:1, which contradicts the continuous increase
of the peroxidase activity at higher peptide excesses.
These apparently discrepant results may be explained
by the fact that a strong peroxidase activity leads
to the over-oxidation of tyrosine to products like
trityrosine, isotrityrosine, and pulcherosine, which
decrease the amount of dityrosine [71, 72]. Both
upon direct addition of H2O2 and by applying the
G/GO-system a greater dityrosine yield was obtained
at higher H2O2 concentrations, which suggests that
multiple peroxidase cycles of the A-heme com-
plexes are needed per dityrosine molecule to be
formed.
Another new aspect addressed in this work is the
effect of the A1-16 sequence on the dityrosine for-
mation. In line with others, in the absence Y10 we
observed no dityrosine formation at all, proving the
specificity of the fluorescence measurements [19, 25].
Yet by testing single and double mutants of human
A1-16, we also observed an influence of R5, H13,
and H14 on the dityrosine yield: Strangely enough,
by replacing the named amino acids by the rodent
or an artificial equivalent, we always observed an at
least slightly higher dityrosine formation. The most
striking differences were observed for the H13R sin-
gle mutant and the H13G, H14G double mutant were
a doubled (H13R) and a not significantly reduced
(H13G, H14G) dityrosine yield coincide with a
slightly (H13R) or strongly (H13G, H14G) reduced
peroxidase activity. As the named histidine residues
are responsible for the proximal heme coordination,
we guess that their replacement leads to the formation
of less stable A-heme complexes [19]. Accordingly,
a lower peroxidase activity is observed, which, how-
ever, may translate to a higher dityrosine yield as
over-oxidations and/or the formation of other tyrosine
oxidation products than dityrosine are diminished
[71, 72].
To confirm the formation of dityrosine upon A-
heme peroxidase activity, we also performed selected
MALDI-TOF measurements. While in the presence
of H2O2 we were able to show a minor dityrosine
formation in the presence of free heme and a mod-
erate product formation in the presence of HRP, the
obtained product yields are scarcely comparable to
the fluorescence measurements. Given the limited
quantification of mass spectrometry data, in future
studies dityrosine antibodies [19, 21, 25] or thin-
layer chromatography [71] should be applied. As
a mechanism for the reported dityrosine formation,
we propose a direct one-electronic oxidation by the
activated A-heme peroxidase [73], followed by a
recombination of the formed tyrosyl radicals. In fact,
Y10 is located directly at the active site of in A-heme
complexes, suggesting a direct oxidation by the acti-
vated oxoferryl state [28]. Yet it has to be stated that
free ROS, including hydroxyl radicals (•OH) [74],
may also lead to A-derived dityrosine formation
under oxidative stress conditions of AD [42].
In summary, the obtained results clearly show the
formation of dityrosine from Y10 due to the per-
oxidase activity of A-heme complexes. As already
reported in the literature the Y10-derived dityrosine
formation in the presence of H2O2 [25] promotes
the aggregation of A via stabilization of peptide
dimers [21, 28, 29], which may be relevant for the
progression of AD.
The formation of Aβ-heme complexes has several
effects on Aβ fibril formation
Yet while A-heme complex-mediated dityrosine
formation promotes the fibrillation of the peptide,
free heme is well known to inhibits A aggrega-
tion [33] and even leads to the dismantling of partly
formed fibrils [26, 31]. In fact, free heme inter-
acts both with H13/H14, leading to the formation
of peroxidase-active A-heme complexes [27], and
with F19/F20, which inhibits the fibrillation of the
peptide [3, 26, 33]. Yet the mentioned studies on A
fibrillation in the presence of free heme have often
been performed only at low A-heme ratios [26, 31],
lack long-term observation [31] and do not include
the application of H2O2 [75] as a precondition for
the A-heme complex-derived dityrosine formation.
By using ThT-based fluorescence measurements [31],
in this study the named issues were addressed and
clearly showed that even at low ratios (50:0.1) free
heme already starts to delay and inhibit the forma-
tion of A fibrils. Still it has to be stated that the
initial interaction of ThT with the negatively charged
peptide is of electrostatic nature [44, 45], which may
provide an additional explanation for the observed
lower fluorescence values.
Most interestingly also H2O2 itself apparently dis-
turbed the formation of peptide fibrils. Yet these
results may also be explained by the fact that oxi-
dized A fibrils yield a weaker fluorescence signal
than native ones during the ThT measurements [21].
Moreover, we cannot rule out a direct oxidation of
the dye. The same holds for the measurements in the
presence of H2O2 and heme or HRP as well as for the
E. Chiziane et al. / Free Heme at Alzheimer’s Disease 979
HRP control. One interesting aspect observed during
the measurements with ThT is the different kinetics
in the fluorescence increase observed after applica-
tion of 1 M HRP or 10 M heme and H2O2: In
both cases a hyperbolic instead of sigmoidal fluores-
cence increase was observed. To our knowledge, such
results were never obtained before and may indicate
a completely different fibrillation behavior of A in
the presence of peroxidase activity [47].
The also performed STEM measurements clearly
showed that despite the (apparent) inhibitory effect of
heme, H2O2, and HRP on the A fibrillation within
the first 96 h, in all samples a peptide fibrillation
finally takes place. Thereby A fibrils with a diam-
eter of about 14 nm were always observed, which is
in the expected range [21, 34]. Still, while in the sole
or combined presence of H2O2 or low amounts of
free heme, the fibrils strongly resembled the control
(A1-40 alone) at higher heme concentrations or in
the presence of HRP different fibril morphologies
were found. These results are in line with others [21]
who also observed different fibril networks under
oxidative conditions [21]. The observed denser fibril
networks in the sole presence of higher heme con-
centrations are somewhat surprising as no peroxidase
activity should take place in the absence of H2O2.
Yet it may be explained by the release of free iron,
which is well known to promote the aggregation of
A [26].
In summary, ThT measurements, especially at the
chosen experimental conditions [44, 45], are a suit-
able tool to show the strong inhibitory effect of free
heme on A fibrillation. Yet they are not completely
reliable under conditions were oxidative processes
take place. Still the STEM measurements clearly indi-
cate that the A-heme complex-derived peroxidase
activity influences the fibril morphology. Most likely
the formation of dityrosine disturbs the classical A
fibrillation pathway, leading to an enhanced forma-
tion of, e.g., protofibrils [34]. This is nicely illustrated
by the positive control (HRP + H2O2) where thinner
and shorter fibrils were observed. Thus, free heme,
upon complexation with A, subsequent peroxidase
activity and dityrosine formation, actually seems
to promote the dimerization/oligomerization of the
peptide.
Fig. 8. Proposed model for A-derived microvessel destruction and hemolysis as a source for cerebral free heme. While monomeric A
readily crosses the blood-brain barrier, A fibrils deposit around cerebral blood vessels and lead to microhemorrhages. A subsequent A
monomer and/or fibril-derived hemolysis of erythrocytes leads to the accumulation of free heme in the brain tissue. Especially in the presence
of elevated cerebral A levels, these processes will lead to the formation of A-heme complexes, which, in the presence of H2O2, exhibit
a peroxidase activity. The latter causes, e.g., oxidative stress in the brain tissue, neuronal death, and neurotransmitter destruction, thus, may
considerably contribute to the pathology of AD.
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While Alzheimer plaques contain both A1-40 and
A1-42, in the current study, the shorter peptide was
used as it was already discussed as the more toxic
one, maybe due to its slower aggregation as com-
pared to A1-42 [16]. Moreover besides this small
difference in the aggregation kinetics both peptides
were reported to be well comparable regarding their
affinity toward heme [33]. Thus, our results are most
likely well transferable to A1-42.
Yet it has to be clearly stated that the peroxidase
activity measurements performed with A1-16 are
only partly comparable to the aggregation studies
performed with the full length peptide: As discussed
in a recent publication [61], free heme most likely
binds not only to H13/H14 in the hydrophilic part
of the peptide but also to F19/20 in the hydrophobic
part of A1-40/42 [26, 27]. In fact, the latter second
heme binding site was already shown to affect the
peroxidase activity of A-heme complexes [37].
Most interestingly as even in mature A fibrils
the amino acids responsible for the formation of
peroxidase-active A-heme complexes (R5, Y10,
H13/H14) are part of the unstructured solvent-facing
side chains [11, 76, 77]. Accordingly, the aggregation
state of the peptide was shown to have no influ-
ence on this enzymatic activity [3, 37]. In fact, a
recent review shows a positive correlation between
A aggregation and the peroxidase activity of A-
heme complexes [61]. In line with our results, this
effect is attributed to peroxidase complexes with an
A-heme ratio higher than one [28, 61]. The last
question addressed in this study refers to possible
sources of free heme as a precondition for the forma-
tion of A-heme complexes in the brain tissue of AD
patients.
Aβ-derived CAA and hemolysis could lead
to the formation of Aβ-heme complexes
We also performed MRA measurements and, as
reported before [49], detected a decreased blood flow
in Tg2576 mice as compared to the healthy control.
Thereby in line with others [53, 66], a clear correla-
tion with the vascular deposition of A was observed.
Furthermore, in the animals a co-localization of free
iron with A plaques was found, which again con-
firms published results [20, 21].
Originally a disturbed mitochondrial heme
metabolism in neurons was suggested as a source
for free heme and iron in the brain [23, 78]. Yet,
based on the obtained results and literature studies,
we suggest that hemoglobin may represent the major
for cerebral free heme in AD. As illustrated in
Fig. 8, the vascular deposition of A (CAA) [6],
resulting cerebral microhemorrhages [53, 68] and
the hemolytic effect of the peptide [54, 66] could
account as the major mechanisms. This theory is
confirmed by the fact that hemolysis-associated
acute phase proteins like Hpx [4, 79] and heme
oxygenase 1 [80, 81] show a higher expression in AD
patients. Moreover, hemoglobin-derived peptides
are elevated in the brain of AD patients [82].
In blood, A is quickly taken up by erythro-
cytes and leads to increased cell sizes and decreased
deformability of the cells [66, 67]. This effect, which
leads to hemolytic events in the tight brain capil-
laries [83], was already attributed to the induction
of oxidative stress in the erythrocytes [54, 84].
Thus, we cannot rule out a contribution of A-
heme complex-mediated peroxidase activity during
these processes. Most interestingly, A was also
shown to inactivate catalase in erythrocytes, lead-
ing to an increased H2O2 concentration in these cells
[85]. Moreover, A-derived phospholipid oxidation
in erythrocytes leads to increased endothelial bind-
ing of the cells [86, 87] and vascular destructions
[86], providing positive feedback mechanisms for
the accumulation of erythrocytes and free heme in
the brain tissue. Up to micromolar cerebral heme
concentrations were found in AD patients [28]. In
addition endothelial and smooth muscle cells of cere-
bral microvessels can also produce APP [53], a
process, which may be elevated upon A-derived
microhemorrhages.
Thus, the presented in vivo results confirm already
published pathological features of AD, including
CAA as well as the coinciding deposition of A
plaques and free iron. Still, considering literature data
these observations may represent final remains of
A-derived microhemorrhagic and hemolytic events,
which could lead to the formation of blood-derived
A-heme complexes as a possible hallmark of AD
pathology. Accordingly, AD was already suggested
as a thrombohemorrhagic disorder [88] whereby A-
heme complexes play a key role [20]. In fact, these
complexes are most likely also formed in vivo and the
resulting peroxidase activity contributes to the pathol-
ogy of AD [89]. In order to prove the connection
between CAA, in future studies we will try to detect
free heme in the brain tissue of Tg2576 mice [28].
Furthermore dityrosine formation in the brain tissue
of this AD model will also be addressed [90]. In sum-
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mary, realizing the peroxidase activity of A-heme
complexes as an important pathological mechanism
of this neurodegenerative disease may open the door
for the development of new therapeutic strategies,
including the application of antioxidants [22, 24]
and/or heme peroxidase inhibitors [34]. Recently also
the binding of free heme to the tau protein was
shown [91], suggesting an even broader role of free
heme at AD. Hyperphosphorylated tau protein and
tau-containing neurofibrillary tangles are major hall-
marks of AD besides A plaques [20, 92].
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